| Company Announcements: (reported by the Company) |
No items found
|
| Elevator Pitch: | MycRx is developing oral, small molecule inhibitors that directly target Myc, oncology's 'mega target'. A key driver of all 'Hallmarks of Cancer', >1M new cancer patients are diagnosed annually with overexpressed Myc protein. MycRx compounds display potent cellular Myc target engagement driving profound transcriptional inhibition & on-target mechanistic profiles, resulting in compelling anti-cancer activity. Ready for Late Lead Optimization, our chemistry is on a clear path to development candidate nomination, underpinned by proprietary structural biology revealing a unique, druggable site, potentially a key breakthrough in drugging Myc. Originally based in Melbourne, Australia, MycRx closed a Series A US-led venture capital round and has restructured as a Delaware corporation, with a growing North American Management team. |
| Category: | Health & biotech |
| URL: | http://mycrxpharma.com |
| Operational Status: | |
| ASX Listing Code (if applicable): | |
| Year of Commencement: | 2013 |
| Address: | Melbourne, AU |
| State: | Victoria |
| Overseas Operations: | |
| X: | |
| Facebook: | |
| Linkedin: | https://www.linkedin.com/company/mycrx |
| Founders: |
No items found
|
| Awards won: | |
